<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>An 82-year-old female was diagnosed with <z:e sem="disease" ids="C0007113" disease_type="Neoplastic Process" abbrv="">rectal cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Hartmann's procedure was performed and a curative resection was successfully achieved </plain></SENT>
<SENT sid="2" pm="."><plain>Postoperative staging according to the classification of the Japanese Society for <z:e sem="disease" ids="C0007102" disease_type="Neoplastic Process" abbrv="">Cancer of the Colon</z:e> and Rectum(The 7th Edition)was stage III </plain></SENT>
<SENT sid="3" pm="."><plain>She received adjuvant chemotherapy after surgery with tegafur(UFT 300 mg/body/day)orally for 6 months </plain></SENT>
<SENT sid="4" pm="."><plain>One year after the surgery, paraaortic lymph node <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> and a local recurrence were diagnosed </plain></SENT>
<SENT sid="5" pm="."><plain>She was treated with modified FOLFOX6 chemotherapy combined with bevacizumab </plain></SENT>
<SENT sid="6" pm="."><plain>After 13 courses of treatment with FOLFOX6 and bevacizumab, multiple <z:e sem="disease" ids="C0153676" disease_type="Neoplastic Process" abbrv="">lung metastases</z:e> were found </plain></SENT>
<SENT sid="7" pm="."><plain>Therefore, we changed the chemotherapy regimens to FOLFIRI plus cetuximab </plain></SENT>
<SENT sid="8" pm="."><plain>After 18 weeks of this new treatment she had two <z:mp ids='MP_0001209'>skin ulcerations</z:mp> around her stoma, a known side effect associated with cetuximab </plain></SENT>
<SENT sid="9" pm="."><plain>We stopped cetuximab and continued chemotherapy with FOLFIRI alone </plain></SENT>
<SENT sid="10" pm="."><plain>Seven weeks after cetuximab withdrawal, her <z:hpo ids='HP_0200042'>skin ulcer</z:hpo> healed with the support of a dermatologist and a wound ostomy continence nurse </plain></SENT>
<SENT sid="11" pm="."><plain>We reintroduced cetuximab in a chemotherapy regimen with a reduced dose </plain></SENT>
<SENT sid="12" pm="."><plain>After two infusions of cetuximab, <z:mp ids='MP_0001209'>skin ulceration</z:mp> recurred </plain></SENT>
<SENT sid="13" pm="."><plain>We stopped cetuximab again and continued chemotherapy with FOLFIRI </plain></SENT>
<SENT sid="14" pm="."><plain>Nine weeks later we resumed cetuximab, but this time the <z:hpo ids='HP_0200042'>skin ulcer</z:hpo> did not occur, and we were able to continue the chemotherapy regimen with FOLFIRI and cetuximab </plain></SENT>
</text></document>